Study Objective: To establish the objective efficacy and safety results recorded with Kineret® (Anakinra) for ECD patients and its effect on various symptoms and organs. This study is opened to ECD patients who are or have been previously treated with Kineret® (Anakinra).
Principal Investigator: Dr. Achille Aouba, Department of Internal Medicine and Clinical Immunology, CHU Côte de Nacre-Caen, FRANCE
Contact Information: achille.aouba@gmail.com or aouba-a@chu-caen.fr; Tel: 00 33 2 31 06 45 79; Fax: 00 33 2 31 06 49 54
Requested Patient Involvement: Consent to have your doctor supply the principal investigator with information about your case. You will be asked to agree to have the following information shared:
- Demographic data in the form of your initials, weight, gender and date of birth
- Clinical, laboratory and radiological data before, during and possibly after treatment with Kineret® to establish whether or not the treatment was effective and well tolerated with reference to every symptom and organ
- Therapeutic data concerning the Kineret® treatment start dates and any treatments administered before or after Kineret® with details of the results, tolerance and reasons for introducing or discontinuing treatment, as applicable.